Solid Biosciences (SLDB) CRO receives equity awards and sells shares

Rhea-AI Filing Summary

Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported equity vesting, new grants, and a tax-related share sale. On January 29, 2026, 54,925 performance stock units converted into common stock and 190,000 employee stock options plus 95,000 restricted stock units were granted.

On January 31, 2026, 27,625 restricted stock units vested into common shares. On February 2, 2026, 26,535 common shares were sold at a weighted average price of $6.4369 to cover withholding taxes under a pre-established automatic sell-to-cover instruction, leaving 82,675 common shares held directly.

Insider Trade Summary

Net Seller: 26,535 shares ($170,803)

Net Sell 7 txns

Insider Hanrahan Jessie

Role Chief Regulatory Officer

Sold 26,535 shs ($171K)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,535	$6.4369	$171K
Exercise	Restricted Stock Units	27,625	$0.00	--
Exercise	Common Stock	27,625	$0.00	--
Exercise	Performance Stock Units	54,925	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	190,000	$0.00	--
Grant/Award	Restricted Stock Units	95,000	$0.00	--
Exercise	Common Stock	54,925	$0.00	--

Holdings After Transaction: Common Stock — 82,675 shares (Direct); Restricted Stock Units — 82,875 shares (Direct); Performance Stock Units — 0 shares (Direct); Employee Stock Option (Right to Buy) — 190,000 shares (Direct)

Footnotes (1)

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 110,500 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanrahan Jessie

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Regulatory Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/29/2026		M		54,925	A	(1)	81,585	D
Common Stock	01/31/2026		M		27,625	A	(2)	109,210	D
Common Stock	02/02/2026		S		26,535(3)	D	$6.4369(4)	82,675	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	01/29/2026		M			54,925	(5)	(5)	Common Stock	54,925	$0.00	0	D
Employee Stock Option (Right to Buy)	$6.6	01/29/2026		A		190,000		(6)	01/29/2036	Common Stock	190,000	$0.00	190,000	D
Restricted Stock Units	(2)	01/29/2026		A		95,000		(7)	(7)	Common Stock	95,000	$0.00	95,000	D
Restricted Stock Units	(2)	01/31/2026		M			27,625	(8)	(8)	Common Stock	27,625	$0.00	82,875	D

Explanation of Responses:

1. Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

2. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

3. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

5. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

6. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

7. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

8. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 110,500 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Jessie Hanrahan	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did SLDB’s Chief Regulatory Officer report on this Form 4?

The Form 4 shows Jessie Hanrahan had performance and restricted stock units vest, received new stock option and RSU grants, and sold 26,535 common shares to cover withholding taxes. These transactions changed her mix of stock, options, and unvested awards but followed preset compensation terms.

How many Solid Biosciences shares did Jessie Hanrahan sell and at what price?

She sold 26,535 shares of Solid Biosciences common stock at a weighted average price of $6.4369 per share. The filing notes the sale was executed in multiple trades between $6.295 and $6.580 and was used solely to cover tax withholding obligations.

Were the SLDB share sales by Jessie Hanrahan discretionary trades?

The sale was not a discretionary trade by Jessie Hanrahan. It was executed under a durable automatic sale instruction letter adopted on August 16, 2024, specifically to effect a sell-to-cover election for taxes after previously granted performance stock units vested.

What new equity awards did the SLDB Chief Regulatory Officer receive?

On January 29, 2026, she received 190,000 employee stock options and 95,000 restricted stock units. The options vest over four years with 25% after one year, then monthly, while the RSUs vest in four equal annual installments from the 2026 grant date.

How many Solid Biosciences shares does Jessie Hanrahan hold after these transactions?

After the February 2, 2026 tax-related sale, she directly owned 82,675 shares of Solid Biosciences common stock. She also held 190,000 stock options and 95,000 restricted stock units, plus additional RSUs from a 2025 grant that continue to vest over time.

What triggered the vesting of the performance stock units for SLDB’s CRO?

The performance stock units vested when the first predefined performance milestone was certified as achieved on January 29, 2026. This milestone related to non-market, non-financial business objectives set by the board, causing 25% of the underlying shares, or 54,925 PSUs, to convert into common stock.